Biota Pharmaceuticals Inc. (AVIR) Receives “Buy” Rating from HC Wainwright
Biota Pharmaceuticals Inc. (NASDAQ:AVIR)‘s stock had its “buy” rating restated by research analysts at HC Wainwright in a research note issued to investors on Tuesday.
Separately, FBR & Co reissued an “outperform” rating on shares of Biota Pharmaceuticals in a research note on Tuesday, May 31st.
Shares of Biota Pharmaceuticals (NASDAQ:AVIR) traded up 6.62% during trading on Tuesday, reaching $1.61. 59,819 shares of the company were exchanged. The stock’s market capitalization is $62.21 million. Biota Pharmaceuticals has a one year low of $1.23 and a one year high of $2.31. The stock has a 50-day moving average price of $1.37 and a 200-day moving average price of $1.46.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/20/biota-pharmaceuticals-inc-avir-receives-buy-rating-from-hc-wainwright.html
Biota Pharmaceuticals (NASDAQ:AVIR) last released its quarterly earnings results on Wednesday, September 14th. The company reported ($0.18) EPS for the quarter, missing the Zacks’ consensus estimate of $0.25 by $0.43. Biota Pharmaceuticals had a negative return on equity of 46.02% and a negative net margin of 272.04%. Analysts forecast that Biota Pharmaceuticals will post ($0.89) EPS for the current year.
Large investors have recently made changes to their positions in the stock. Towerview LLC acquired a new stake in shares of Biota Pharmaceuticals during the second quarter worth about $224,000. California Public Employees Retirement System acquired a new stake in shares of Biota Pharmaceuticals during the second quarter worth about $139,000. Gabelli Securities Inc. acquired a new stake in shares of Biota Pharmaceuticals during the second quarter worth about $314,000. Dimensional Fund Advisors LP acquired a new stake in shares of Biota Pharmaceuticals during the second quarter worth about $290,000. Finally, Vanguard Group Inc. acquired a new stake in shares of Biota Pharmaceuticals during the second quarter worth about $1,462,000. 34.53% of the stock is owned by institutional investors.
About Biota Pharmaceuticals
Aviragen Therapeutics, Inc, formerly Biota Pharmaceuticals Inc, is a biopharmaceutical company. The Company is focused on the discovery and development of direct-acting antivirals to treat infections. It has approximately four product candidates in clinical development that address viral infections that have limited therapeutic options.
Receive News & Ratings for Biota Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biota Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.